Abstract:We have recently characterized a unique CD8 T cell subset that expresses NKG2C, as well as multiple other natural killer cell markers. These NKG2C+ CD8 T cells demonstrate NK-like effector functions against various tumor targets, can be efficiently expanded and engineered using GMP-compatible techniques, and most importantly, display beneficial qualities unique to T and NK cells while minimizing the therapeutic deficits of each. NKG2C+ CD8 cells can be easily expanded using a genetically modified K562 feeder line and can be efficiently engineered via retroviral transduction. We genetically engineered NKG2C+ CD8 T cells to express an anti-CD19-28-z CAR construct to target B cell malignancies and compared effector functions of the CAR-engineered NKG2C+ CD8 T cells against CAR+NKG2C- (conventional) CD8 T cells and CAR+ NK cells in vitro and in vivo. We examined expansion, engineering efficiency, tumor control, and extent of cytokine release syndrome (CRS). We also engineered NKG2C+ CD8 T cells with a transgenic NY-ESO-1 TCR to target melanoma and compared the functional responses and efficacy of TCR-engineered NKG2C+ CD8 T cells against TCR-engineered conventional CD8 T cells. CAR+NKG2C+ CD8 T cells demonstrated superior in vitro effector function when compared to CAR+ conventional CD8 T cells and CAR+NK cells and did not upregulate characteristic T cell exhaustion markers, such as PD-1, TIM-3, and LAG-3. These CAR+NKG2C+ CD8 T cells demonstrated superior control of a CD19+ NALM6 tumor model in NRG mice, which was further enhanced with administration of IL-15. CAR+NKG2C+ CD8 T cells with IL-15 demonstrate dramatic and enhanced persistence, as well as superior cytotoxicity and activation in vivo when compared to CAR+ conventional CD8 T cells and CAR+ NK cells. Using a SCID-beige CRS mouse model, we observed reduced CRS in mice treated with CAR+ NKG2C+ CD8 T cells than in mice treated with CAR+ conventional CD8 T cells, with lower levels of proinflammatory cytokines and minimal expansion of murine myeloid subsets. Similarly, TCR-engineered NKG2C+ CD8 T cells demonstrated enhanced tumor control and in vivo persistence in an A375 melanoma-bearing NRG mouse model compared to TCR-engineered conventional CD8 T cells. We have successfully demonstrated that CAR- or TCR-engineered NKG2C+ CD8 T cells have superior anti-tumor efficacy, in vitro and in vivo, to conventional CD8 T cell and NK cell counterparts due to their innate tumor killing and greater in vivo persistence. These cells mediate less CRS and provide a safer alternative to traditional engineered T cell therapeutics. Ultimately, our NKG2C+ CD8 T cells represent a unique platform for engineered T cell therapies to target both solid tumors and hematologic malignancies, that is easily expanded ex vivo, does not require CD4 T cells for in vivo persistence, and is resistant to exhaustion. Citation Format: Kyle Lupo, M. Kazim Panjwani, Anthony Daniyan, Christopher Klebanoff, Katharine Hsu. Engineered NK-like NKG2C+ CD8 T cells mediate superior anti-tumor efficacy over conventional CD8 T cells and NK cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5233.

Enhanced CCR2 expression by ACKR2-deficient NK cells increases tumoricidal cell therapy efficacy

Targeting the Atypical Chemokine Receptor 2 (ACKR2) improves the benefit of anti-PD-1 immunotherapy in melanoma

KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies

Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma

NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs

NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention

Overexpressed Cxcr4 And Ccr7 On The Surface Of Nk92 Cell Have Improved Migration And Anti-Tumor Activity In Human Colon Tumor Model

Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases

CDX2 Enhances Natural Killer Cell-Mediated Immunotherapy Against Head and Neck Squamous Cell Carcinoma Through Up-Regulating CXCL14

Abstract 3966: NK receptors enable TCR-mediated CTL recognition and killing of cancer cells expressing non-mutated tumor-associated antigens

Engineered NKG2C+ NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome

The CCR2/MCP-1 Chemokine Pathway and Lung Adenocarcinoma

Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy

Abstract C010: Tumor MK2 drives tumor progression and an immunosuppressive microenvironment in head and neck squamous cell carcinoma

High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells

CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency

Abstract 5233: Engineered NK-like NKG2C+ CD8 T cells mediate superior anti-tumor efficacy over conventional CD8 T cells and NK cells

Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19

CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma

Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells

C3aR Signaling Inhibits NK-cell Infiltration into the Tumor Microenvironment in Mouse Models